The Efficacy of Qianglidingxuan Tablets in the Treatment of Hypertension

Exclusion Criteria

• •1. Secondary hypertension: renal hypertension (renovascular hypertension, renal parenchymal hypertension), pheochromocytoma, primary aldosteronism, Cushing syndrome, abdominal aortic coarctation, etc.
• •2. Coronary atherosclerotic heart disease, acute attack of chronic heart failure, malignant arrhythmia, valvular heart disease, cardiomyopathy and other serious cardiovascular diseases.
• •3. Acute cerebrovascular diseases such as cerebral infarction and cerebral hemorrhage.
• •4. Severe psychological disorder, intellectual disability or language disorder, resulting in inability to fully cooperate with the study and inability to complete the study.
• •5. Any laboratory test index before screening met the following criteria: admission liver and kidney function indicated that ALT, AST \> 1.5 times the upper limit of normal value, Cr \> 1.2 times the upper limit of normal value (refer to the laboratory normal range of the research center); Other clinically significant laboratory abnormalities that were deemed unsuitable for enrollment by the investigator.
• •6. Allergic constitution or allergic to strong fixed glare tablets, excipients or similar ingredients of the trial drug.
• •7. Suspected or with a history of alcohol or drug abuse.
• •8. Pregnant, lactating women or those who plan to get pregnant recently or are unwilling to use contraceptive measures;.
• •9. Patients who had participated in other clinical trials within 3 months before enrollment.
• •10. Patients deemed by the investigator to be ineligible for enrollment in the trial.